Dallas, Texas (PRWEB) November 10, 2012
The US seasonal influenza vaccine market is the most attractive of those covered in the report in terms of value. It is forecast to increase from $ 1.6 billion in 2011 to $ 2.2 billion in 2018 at a CAGR of 4.8%, due to the growth of the aging population, higher disease awareness and the fact that being vaccinated has become more convenient. The UK on the other hand has the most attractive market in terms of growth rate, forecast to grow at CAGR of 6.3% between 2011 and 2018. Germanys market is also attractive and is forecast to grow at a CAGR of 2.7% between 2011 and 2018 from $ 385.5m to $ 465m. The market in Japan is forecast to grow at CAGR of 1.6% between 2011 and 2018 to reach $ 621.5m by 2018, driven by the threat of pandemic influenza and higher awareness of influenza vaccination. The government-run influenza immunization program is also helping to increase vaccination coverage.
Analysis shows that the R&D pipeline for seasonal influenza vaccines market comprises a high number of vaccines in early-stage development, many of which are new formulations or those that have been developed using the cell culture method. Late-stage vaccines are either quadrivalent vaccines or pediatric versions of those that have already been approved. The market is currently dominated by trivalent vaccines but will witness the launch of quadrivalent vaccines in the near future.
Buy your copy of this report @ http://www.reportsnreports.com/reports/202051-seasonal-influenza-vaccines-market-in-top-seven-countries-to-2018-next-generation-quadrivalent-vaccines-to-dominate-the-market-by-offering-broader-protection-via-single-dose.html.
The vaccine industry has seen changes in the past year, and these are covered in the report Vaccines 2012: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimers disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinsons disease, West Nile virus (WNV) infection, etc. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth through 2011 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.
Included in this report are current market size and forecast for the following vaccines:
Pediatric Vaccines: